Drug administration in chronic liver disease

Area of Science:

• Pharmacology
• Hepatology
• Clinical Pharmacy

Background:

• Cirrhosis causes pathophysiological changes affecting drug disposition.
• Hepatic insufficiency unpredictably alters drug elimination and can lead to accumulation.
• Coexisting kidney dysfunction further complicates drug pharmacokinetic forecasting in cirrhosis.

Purpose of the Study:

• To review the impact of cirrhosis on drug disposition and clinical outcomes.
• To identify drugs commonly associated with adverse events in liver disease patients.
• To provide guidance on drug selection and management in cirrhosis.

Main Methods:

• Literature review of drug disposition in cirrhosis.
• Analysis of pharmacokinetic alterations and adverse drug reactions.
• Synthesis of clinical implications for drug therapy.

Main Results:

• Drugs primarily cleared by the liver may accumulate, but are not the most common cause of adverse events.
• Furosemide can cause electrolyte disturbances and hepatorenal syndrome.
• Altered tissue responsiveness (e.g., brain, kidneys) and interference with physiological adaptations are significant concerns.

Conclusions:

• Drug effects in cirrhosis are complex and unpredictable, necessitating empirical dosing and monitoring.
• Certain drug classes (e.g., ACE inhibitors, NSAIDs, some calcium antagonists, specific beta-lactams) should be avoided.
• Special caution is advised for paracetamol in alcoholic liver disease due to potentiated hepatotoxicity.